NCT05548491View on ClinicalTrials.gov

Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD)

PHASE2CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

November 10, 2022

Primary Completion Date

October 13, 2023

Study Completion Date

October 13, 2023

Conditions
Contact Lens Discomfort
Interventions
DRUG

AZR-MD-001 ointment/semi-solid drug

ointment/semi-solid drug

Trial Locations (2)

Unknown

University of New South Wales, School of Optometry and Vision Science, Sydney

Ophthalmic Trials Australia, Teneriffe

Sponsors

Lead Sponsor

Azura Ophthalmics

Collaborators (1)

Avania
All Listed Sponsors
collaborator

Avania

INDUSTRY

lead

Azura Ophthalmics

INDUSTRY

NCT05548491 - Safety, Tolerability and Pharmacodynamics of AZR-MD-001 in Contact Lens Discomfort (CLD) | Biotech Hunter | Biotech Hunter